Company Overview - Akari Therapeutics is a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for cancer treatment [3] - The company has developed its first novel payload, PH1, which is a spliceosome modulator designed to disrupt RNA splicing within cells [3] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers the PH1 payload directly into tumors [3] Product Development - PH1 is differentiated from current ADC payloads that typically use Topoisomerase1 inhibitors or tubulin inhibitors, showing potential to induce cancer cell death while activating immune cells [3] - In preclinical studies, AKTX-101 has demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - AKTX-101 has the potential to work synergistically with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination with these inhibitors [3] Upcoming Events - Akari Therapeutics will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:00 PM ET [1]

Core Viewpoint - Jet.AI Inc. has made a capital contribution to AIIA Sponsor Ltd., which is sponsoring AI Infrastructure Acquisition Corp., a special purpose acquisition company aiming for an initial public offering (IPO) focused on AI and machine learning technology companies [1][2]. Group 1: Company Overview - Jet.AI Inc. is a provider of high-performance GPU infrastructure and AI cloud services, transitioning to a pure-play AI data center company [5]. - The company was founded in 2018 and is based in Las Vegas, NV, operating in two segments: Software and Aviation [5]. - Jet.AI aims to build scalable, high-performance infrastructure to meet the growing computational demands of artificial intelligence [5]. Group 2: IPO Details - AI Infrastructure Acquisition Corp. plans to conduct an IPO with a base offering size of $100 million, potentially increasing to $115 million if the underwriters fully exercise their over-allotment option [2]. - The IPO will focus on high-impact private technology companies that advance AI and machine learning capabilities, as well as those involved in next-generation data center infrastructure [2]. - Maxim Group LLC is acting as the sole book-running manager for the IPO [3].

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Presentation - Senti Bio will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:20 PM ET [1] - The presentation will be led by Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio [1] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Core Viewpoint - Wrap Technologies, Inc. has launched Project PAN-DA, a handheld counter-drone system derived from its BolaWrap® 150 platform, aimed at addressing the growing global counter-unmanned aircraft systems (C-UAS) market, projected to reach $6.8 billion by 2030 [1][6]. Company Overview - Wrap Technologies is a leader in innovative public safety technology, focusing on non-lethal tools and solutions for law enforcement and public safety organizations [14]. - The company has a proven track record with its BolaWrap® 150 device, which is used by over 1,000 law enforcement agencies worldwide [15]. Product Development - Project PAN-DA is designed to engage and disable small unmanned aerial systems (sUAS) at close range, providing a cost-effective and reusable alternative to traditional missile interceptors and electronic jamming systems [3][4]. - The system utilizes Wrap's patented tether-and-anchor technology, allowing for multiple engagements per unit, enhancing operational efficiency [3][4]. Market Context - The global counter-drone market is expected to grow from $1.9 billion in 2023 to over $6.8 billion by 2030, driven by the increasing use of small UAS in criminal and military activities [6]. - PAN-DA is positioned as a last-line kinetic defense option that complements existing detection and electronic countermeasure systems [6]. Research and Development - Following the successful proof of concept for Phase One, Wrap's engineering teams will focus on enhancing the system's range, area-of-effect, and cost-effectiveness to adapt to evolving drone threats [8].

Live video webcast on Wednesday, August 20th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as foll ...

LAS VEGAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- All American Gold Corp. (OTC: AAGC) is delighted to update the public about the Company’s exciting new concept in the Beauty industry. Hollywood Star Cuts (A Family Salon) and All American Gold Corp. (AAGC) have finalized an agreement with a Franchise group based in San Diego, CA, to launch a concept that will complement the proven Hollywood Star Cuts model in exclusive areas. Hollywood Star Salons is an exciting new platform set to debut in October 2025 in Encin ...

Core Insights - North Media reported Q2 2025 revenue of DKK 342 million, slightly down from DKK 343 million in Q2 2024, with a stable trend in Last Mile services and a 2% increase in Digital Services driven by BoligPortal [1] - The company has revised its full-year revenue guidance for 2025 to DKK 1,270–1,315 million, down from the previous range of DKK 1,280–1,337 million, while EBITDA and EBIT guidance has been upgraded [2][5] - The improvement in EBITDA and EBIT is primarily due to enhanced operations at SDR, leading to more stable planning and lower unit costs, with Bekey also contributing positively [3] Financial Performance - Q2 2025 EBITDA was DKK 48 million, down from DKK 61 million in Q2 2024, and EBIT was DKK 32 million compared to DKK 44 million in the previous year [1] - The revised guidance for 2025 includes EBITDA expectations of DKK 105–130 million, up from DKK 80–115 million, and EBIT expectations of DKK 50–75 million, up from DKK 25–60 million [2][5] Business Segments - North Media operates in two main business areas: Last Mile, which includes FK Distribution and SDR Svensk Direktreklam, and Digital Services, which encompasses BoligPortal, Dayli (MineTilbud), and Bekey [7] - The Last Mile segment is experiencing a slight loss in volumes, while growth in Digital Services, particularly BoligPortal and Dayli, has been lower than expected [4]

Core Viewpoint - Fairfax Financial Holdings Limited has successfully completed an offering of C$400 million in 4.45% Senior Notes due 2035 and C$300 million in 5.10% Senior Notes due 2055, totaling C$700 million in Senior Notes [1][2]. Group 1: Offering Details - The Senior Notes were offered through a syndicate of dealers led by National Bank Financial Inc., RBC Dominion Securities Inc., Scotia Capital Inc., and TD Securities Inc. as joint bookrunners [2]. - The Senior Notes are unsecured obligations of Fairfax [2]. Group 2: Use of Proceeds - Fairfax intends to use the net proceeds from the offering to refinance, repay, or redeem outstanding debt, equity, or other corporate obligations, pursue potential acquisition or investment opportunities, and for general corporate purposes [3]. - Specific determinations regarding the debt, equity, or corporate obligations to be repaid or redeemed have not yet been made, nor have decisions been made regarding specific acquisitions or investments [3]. Group 3: Company Overview - Fairfax is a holding company primarily engaged in property and casualty insurance and reinsurance, along with associated investment management [5].

CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2025 financial results after market close on Thursday, August 28, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the start of t ...

Second Quarter 2025 Highlights XBP Europe Holdings, Inc. (“XBP Europe”) completed the acquisition of Exela Technologies BPA, LLC (“BPA”) and changed its name to XBP Global Holdings, Inc. Revenue of $39.6 million, an increase of 17.8% year-over-year and 5.2% sequentiallyGross margin of 29.8%, a 1,020 bps increase year-over-year and 30 bps decrease sequentially Adjusted EBITDA of $3.3 million, an increase of 173.8% year-over-year and decrease of 11.2% sequentially IRVING, Texas and LONDON, Aug. 14, 2025 (GLOB ...